0A9W Stock Overview
Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 3/6 |
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.19 |
| 52 Week High | US$24.05 |
| 52 Week Low | US$10.89 |
| Beta | 0.77 |
| 1 Month Change | 19.72% |
| 3 Month Change | 14.42% |
| 1 Year Change | 4.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A9W | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.9% | 1.7% | 1.3% |
| 1Y | 4.5% | 7.0% | 6.1% |
Return vs Industry: 0A9W underperformed the UK Pharmaceuticals industry which returned 7% over the past year.
Return vs Market: 0A9W underperformed the UK Market which returned 6.1% over the past year.
Price Volatility
| 0A9W volatility | |
|---|---|
| 0A9W Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0A9W has not had significant price volatility in the past 3 months.
Volatility Over Time: 0A9W's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| 0A9W fundamental statistics | |
|---|---|
| Market cap | US$5.49b |
| Earnings (TTM) | US$1.05b |
| Revenue (TTM) | US$6.35b |
5.2x
P/E Ratio0.9x
P/S RatioIs 0A9W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A9W income statement (TTM) | |
|---|---|
| Revenue | US$6.35b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$3.75b |
| Other Expenses | US$2.70b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.07 |
| Gross Margin | 59.04% |
| Net Profit Margin | 16.50% |
| Debt/Equity Ratio | 18,154.2% |
How did 0A9W perform over the long term?
See historical performance and comparison